FilingReader Intelligence
Haisco drug wins approval for additional clinical trials
August 17, 2025 at 07:51 AM UTC•By FilingReader AI
Haisco Pharmaceutical Group received regulatory acceptance for HSK39297 tablets to undergo clinical trials for age-related macular degeneration and generalized myasthenia gravis.
The drug is already in Phase II and Phase III studies for other conditions including IgA nephropathy and paroxysmal nocturnal hemoglobinuria.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:002653•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Haisco Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime